Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of recombinant human nerve growth factor eye drops in Dry Eye syndrome
2013-004271-12Phase 2Completed
- Sponsor
- Dompé
- Start
- Nov 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cenegermin in dry eye syndrome (DED), sponsored by Dompé. Primary endpoint: Primary efficacy and safety endpoint. Started Nov 2013; status: completed.
02
Drugs
cenegermin
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on 2013-004271-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004271-12.